Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essence

Neurology: Clinical Practice

Volumn 1, Issue 1, 2011, Pages 66-68

  Freedman, Mark S ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; NATALIZUMAB;

ARTICLE; AXONAL INJURY; DISEASE CONTROL; DRUG EFFECT; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; NERVE CELL LESION; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; REMISSION; RISK BENEFIT ANALYSIS;

EID: 84870717089     PISSN: 21630402     EISSN: 21630933     Source Type: Journal    
DOI: 10.1212/CPJ.0b013e31823cc2c2     Document Type: Article

References (7)

1. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
2. Lucchinetti C. Pathological heterogeneity of idiopathic central nervous system inflammatory demyelinating disorders. Curr Top Microbiol Immunol 2008;318:19-43.
3. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923.
4. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
5. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsingremitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2010;10:520-529.
6. Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post hoc and subgroup analysis. Lancet Neurol 2010;10:329-337.
7. Freedman MS. Time is brain' also in multiple sclerosis. Mult Scler 2009;15:1133-1134.